News & Blog

Lexeo Therapeutics Receives Rare Pediatric Disease & Orphan Drug Designations for LX2006

LEXEO Therapeutics Announces License Agreement and Consolidation of Pre-clinical Data Package to Support Cardiac Friedreich’s Ataxia Gene Therapy Program (LX2006)

Larimar Therapeutics Announces $95 Million Private Placement Financing

Larimar Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for CTI-1601 in Friedreich’s Ataxia

Larimar Therapeutics Reports Positive Topline Phase 1 Clinical Trial Data Showing Dose-Dependent Increases in Frataxin Levels in Patients with Friedreich’s Ataxia

Larimar Therapeutics Reports First Quarter 2021 Operating and Financial Results

Lexeo Therapeutics Announces License Agreement and Consolidation of Pre-Clinical Data Package

FA Community Petition

Lexeo Therapeutics Launches with $85 Million Series A Financing to Develop Gene Therapies

Minoryx’s clinical candidate leriglitazone shows clinical benefit in a proof of concept Phase 2 study in Friedreich´s ataxia

Larimar Therapeutics Announces Completion of Dosing of the Single Ascending Dose Clinical Trial in Friedreich’s Ataxia Patients and Provides Program Update

PTC Therapeutics Announces Initiation of Global Phase 3 Clinical Trial to Evaluate Vatiquinone in Friedreich Ataxia